Study of the Therapeutic Effect of Some Hormonal Disorders Associated With Polycystic Ovary Syndrome in Iraqi Women

Background: Polycystic ovary syndrome (PCOS) is a hormonal imbalance resulting from high levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in females, leading to immaturity of eggs, ovarian cysts, irregular menstrual cycle, infertility, excessive facial hair growth, and acne. Materials and Methods: This study was conducted to follow up the therapeutic effect on some blood and hormonal variables of 35 patients with polycystic ovary syndrome (PCOS) from women suffering from infertility and infertility, and who visited Azadi Teaching Hospital and private laboratories in Kirkuk city, their ages ranged between (18 - 40 years). Sample collection and follow-up began by observing some clinical signs in addition to verifying the results of ultrasound examinations from early February 2023 to early November 2023. Each patient’s examinations were followed up before treatment and three months after taking the treatment. Result: The results we obtained after three months of treatment were compared with the results of the examinations of the patients in the pre-treatment stage and the control group. The treatment plan was based on modifying the patient's dietary lifestyle by following a healthy diet and giving treatment represented by oral contraceptives, fertility drugs and the use of sugar-lowering drugs such as Glucophage or Metformin, in addition to nutritional supplements such as antioxidants. Conclusion: The results showed a significant decrease in the level of hemoglobin before and after treatment compared to the control group. Other blood variables did not show any significant differences (0.05 < p). Pituitary hormones (LH, FSH) showed a significant decrease at a significant level (0.000 > p) respectively after three months of continuing to take the treatment. They also showed the therapeutic effect of improving the level of thyroid-stimulating hormone TSH and T3 changed numerically and not significantly after (3) months of taking the treatment compared to the pre-treatment stage and the control group. As for the T4 hormone, it did not show any significant differences during the treatment period. The therapeutic effect on the leptin hormone showed a significant decrease at a level (0.001 > p). ) After three months of taking the treatment compared to the pre-treatment stage and the control group.